Editorial: The choice of thiazide diuretics: Why chlorthalidone may replace hydrochlorothiazide

Hypertension

Volumn 54, Issue 5, 2009, Pages 951-953

  Kaplan, Norman M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ATENOLOL; BENDROFLUMETHIAZIDE; CHLORTALIDONE; CLONIDINE; EPLERENONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; RESERPINE; SPIRONOLACTONE; TRIAMTERENE; TRICHLORMETHIAZIDE; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERTENSION; HYPOKALEMIA; MORTALITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; AGED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UNITED STATES;

AGED; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME; UNITED STATES;

EID: 70449732612     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.135061     Document Type: Editorial

References (29)

1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. JAMA. 1970; 213:1143-1152.
2. Kaplan N, Victor R. Treatment of hypertension: drug therapy. In: Kaplan's Clinical Hypertension. 10th ed. Philadelphia, PA: Lippincott and Wilkins; 2010. In press.
3. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: I-reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562-2571
4. Report by the Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet. 1980;1:1261-1267.
5. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial-The Oslo Study. Am J Med. 1980;69:725-732
6. Medical Research Council Working Party. Medical research council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412
7. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:1616-1628.
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. Hypertension. 2003;42:1206-1252 (Pubitemid 37553153)
9. SHEP Cooperative Research Group. Prevention of stroke by antihyper-tensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-2997.
11. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Kewis CE, Liebson PR. Treatment of Mild Hypertension Study: final results-treatment of Mild Hypertension Study Research Group. JAMA. 1993; 270:713-724.
12. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihyper-tensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
13. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlortha-lidone: evidence supporting their interchangeability. Hypertension. 2004; 43:4-9.
14. Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR. Comparative antihypertensive effects of hydro-chlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-358.
15. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
16. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Long-term antihy-pertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlo-rothiazide. Circulation. 2009;119:417-425.
17. Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation. 2009;119: 371-373.
18. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, Cobb L, Rautaharju PM, Copass MK, Wagner EH. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
19. Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation. 2003;107:2525-2527. (Pubitemid 36628926)
20. Pitt B, Ahmed A, Love TE, Krum H, Nocolau J, Cardoso JS, Park-homenko A, Aschermann M, Corbalan R, Solomon H, Shi H, Zannad F. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension. 2008;52:271-278.
21. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR; for the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845.
22. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117:2706-2715.
23. Lindholm LH, Carlberg B, Samuelsson O. Should /3-blockers remain first choic in the tratmento of primary hypertension? A meta analysis. Lancet. 2005;366:1545-1553.
24. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F, Hamdy R, Joossens JV, Lund-Johansen P, Petrie J, Tuomilehto J, Williams B. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1:1349-1354.
25. PATS Collaborating Group. Post-Stroke Antihypertensive Treatment Study: a preliminary report. Chin Med J (Engl). 1995;108:710-717.
26. Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A, for the VHAS Investigators. Clinical results of the Verapamil in Hypertension and Atherosclosis Study. J Hypertens. 1997;15:1337-1344
27. National Intervention Cooperative Study in Elderly Hypertension Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension. 1999;34:1129-1133.
28. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the international nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.
29. Wing LMH, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ; Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348: 583-592.